Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals Stock
A loss of -1.230% shows a downward development for Vanda Pharmaceuticals.
Vanda Pharmaceuticals is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
Based on the current price of 6.44 € the target price of 17 € shows a potential of 163.98% for Vanda Pharmaceuticals which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Vanda Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Vanda Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vanda Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals | -1.230% | 7.333% | -5.294% | 67.708% | 3.871% | 3.040% | -51.579% |
| Heron Therapeutics Inc. | -1.020% | -1.160% | -18.187% | -61.949% | -38.824% | -67.548% | -95.177% |
| Evolus Inc | 2.310% | -0.562% | -24.681% | -61.730% | -35.046% | -52.162% | -67.222% |
| Sangamo Therapeutics Inc. | -15.030% | 3.873% | -31.655% | -65.685% | -36.364% | -85.038% | -97.651% |
Comments
Vanda Pharmaceuticals (VNDA) is now covered by Truist Financial Corporation. They set a "buy" rating and a $18.00 price target on the stock.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its price target raised by analysts at HC Wainwright from $22.00 to $24.00. They now have a "buy" rating on the stock.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for VNDA provided by MarketBeat